ArticleThe Lancet regional health. Western Pacific2021
Disease burden and attributable risk factors of respiratory infections in China from 1990 to 2019.
Article in The Lancet regional health. Western Pacific, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Pooled it
- Subnational trend and driving factors for pancreatic cancer burden in China, 1990-2021: an analysis based on the Global Burden of Disease Study 2021.Annals of medicine · 2025Article
- Burden of non-COVID-19 lower respiratory infections and etiologies in China and globally: An analysis for the global burden of disease study 2021.Chinese medical journal pulmonary and critical care medicine · 2025Article
- Analysis of disease burden and trends in non-COVID-19 respiratory infections in China (1990-2021).BMC infectious diseases · 2025Article
- Global Trends and Attributable Risk Factors in the Disease Burden of Lower Respiratory Infections.Tropical medicine and infectious disease · 2025Article
- Short-term air pollution exposure and risk of respiratory pathogen infections: an 11-year case-crossover study in Guangzhou, China.BMC public health · 2025Article
- Epidemiological trends and serological profiles of respiratory pathogens in Guangzhou: an 11-year retrospective study from 2013 to 2023.Journal of thoracic disease · 2025Article
- Analysis of Pathogens in Respiratory Tract Infections and Their Effect on Disease Severity: Retrospective Data from a Tertiary Care German Children's Hospital.Children (Basel, Switzerland) · 2025Article
- A 32-year trend analysis of lower respiratory infections in children under 5: insights from the global burden of disease study 2021.Frontiers in public health · 2025Article
- Clinical application of Myxovirus resistance protein A as a diagnostic biomarker to differentiate viral and bacterial respiratory infections in pediatric patients.Frontiers in immunology · 2025Article
- Respiratory pathogens in infants and young children with acute respiratory illness: a prospective cohort study, China, 2023-2024.Frontiers in public health · 2025Article
- Time trends in the burden of non-COVID-19 lower respiratory tract infections among children aged 0 to 14 years.Frontiers in cellular and infection microbiology · 2025Article
- Deep longitudinal lower respiratory tract microbiome profiling reveals genome-resolved functional and evolutionary dynamics in critical illness.Nature communications · 2024Article
- Health impacts of new-onset diabetes in women post-gestational diabetes mellitus: Insights from Hong Kong's territory-wide data.Journal of diabetes investigation · 2024Article
- Risk Factors for COVID-19 and Respiratory Tract Infections during the Coronavirus Pandemic.Vaccines · 2024Article
- Expert consensus on the use of oropharyngeal probiotic Bactoblis in respiratory tract infection and otitis media: available clinical evidence and recommendations for future research.Frontiers in pediatrics · 2024Article
- Article
- Trends of Incidence, Mortality, and Risk Factors for Lower Respiratory Infections among Children under 5 Years in China from 2000 to 2019.International journal of environmental research and public health · 2023Article
- Empirical dynamic modeling of the association between ambient PMEcotoxicology and environmental safety · 2022Article
- Three Exposure Metrics for Fine Particulate Matter Associated With Outpatient Visits for Acute Lower Respiratory Infection Among Children in Guangzhou, China.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere was lack of data on the burdens and trends of upper and lower respiratory infections (URIs and LRIs) over the past three decades in China.
methodsWe estimated the incidence, mortality, and disability-adjusted life years (DALYs) due to upper and lower respiratory infections (URIs and LRIs) and attributable risk factors in China by a systematic analysis of the Global Burden of Disease 2019 study. Incidence, mortality, and DALYs were stratified by sex, age, and province. Risk factors for respiratory infections were analyzed from exposure data.
findingsThe age-standardized incidence rates of URIs and LRIs were 179,077 and 3926 per 100,000 persons in 2019, with a 7•52% and 35•07% decrease from 1990, respectively. Moreover, 2801 and 185,264 persons died of URIs and LRIs in 2019, respectively. DALYs for URIs and LRIs also decreased from 1,516,727 in 1990 to 928,617 in 2019 and from 38,278,504 in 1990 to 4,020,676 in 2019. The burden of URIs and LRIs were generally similar in males and females, but relatively higher in the new-borns and the elderly. Child malnutrition and low birth weight were the most important cause of age-standardized DALYs of LRIs and URIs, respectively.
interpretationFuture URI and LRI prevention strategies should focus on the maternal and child health, air pollution, and tobacco control, especially in young children and the elderly population.
fundingNational Key R&D Program of China (2018YFA0606200); National Natural Science Foundation of China (82041021); Fundamental Research Funds for the Central Universities (20ykpy86) and Guangdong Basic and Applied Basic Research Foundation (2019A1515110003); Bill & Melinda Gates Foundation (No.: INV-006371).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.